Lonza
Lonza Group AG, commonly referred to as Lonza, is a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and specialty ingredients sectors. Headquartered in Switzerland (CH), Lonza operates extensively across Europe, North America, and Asia, delivering innovative products and services that cater to diverse industry needs. Founded in 1897, Lonza has achieved significant milestones, including advancements in cell and gene therapy manufacturing. The company is renowned for its high-quality contract development and manufacturing services (CDMO), as well as its extensive portfolio of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. Lonza's commitment to sustainability and cutting-edge technology positions it as a market leader, consistently recognised for its contributions to the life sciences and healthcare industries.
DitchCarbon Score
How does Lonza's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Furniture Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lonza's score of 70 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lonza's reported carbon emissions
In 2024, Lonza reported total greenhouse gas emissions of approximately 2,187,000,000 kg CO2e, comprising 319,000,000 kg CO2e from Scope 1, 218,000,000 kg CO2e from Scope 2, and a significant 1,878,000,000 kg CO2e from Scope 3 emissions. This reflects a commitment to transparency in their emissions reporting across all scopes. Lonza has set ambitious targets to reduce its carbon footprint. The company aims to achieve a 50% reduction in Scope 1 and 2 emissions intensity by 2030, using 2018 as a baseline. Additionally, they have committed to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, based on a 2021 baseline. This commitment aligns with the Science Based Targets initiative (SBTi) and includes a goal for 79% of their suppliers to adopt science-based targets by 2028. Furthermore, Lonza is pursuing a long-term ambition to achieve net-zero emissions by 2050 or earlier, with a comprehensive climate plan in place to facilitate this transition. The company is actively working on initiatives to reduce energy and waste intensity, aiming for a 50% reduction per million CHF in sales by 2030. Overall, Lonza's climate commitments reflect a proactive approach to sustainability, with clear targets and a focus on reducing emissions across all scopes, particularly in the pharmaceutical and biotechnology sectors.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 574,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 348,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lonza is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
